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Summary
 
Estrogen deficiency causes bone loss, which can be prevented by estrogen replacement therapy.
Using a recently developed technique for isolation of highly purified mammalian osteoclasts,
we showed that 17 
 
b
 
-estradiol (E
 
2
 
) was able to directly inhibit osteoclastic bone resorption. At
concentrations effective for inhibiting bone resorption, E
 
2
 
 also directly induced osteoclast
apoptosis in a dose- and time-dependent manner. ICI164,384 and tamoxifen, as pure and par-
tial antagonists, respectively, completely or partially blocked the effect of E
 
2
 
 on both inhibition
of osteoclastic bone resorption and induction of osteoclast apoptosis. These data suggest that
the protective effects of estrogen against postmenopausal osteoporosis are mediated in part by
the direct induction of apoptosis of the bone-resorbing osteoclasts by an estrogen receptor–
mediated mechanism.
 
E
 
strogen deficiency, caused by either menopause or
ovariectomy, results in pathological bone loss, which
can be prevented by estrogen replacement therapy (1, 2).
Although it is believed that estrogen’s main action in pre-
venting bone loss is through inhibition of osteoclastic bone
resorption, the precise mechanism of such effects is not
clear, largely due to technical difficulties in obtaining puri-
fied functional osteoclasts (3, 4). Osteoclasts are terminally
differentiated multinucleate cells the main function of which
is to dissolve bone matrix and minerals in the resorption
phase of bone remodeling (5). Recruitment, differentiation,
and activity of osteoclasts are tightly controlled by systemic
and local factors. For instance, vitamin D
 
3
 
, prostaglandins,
TGF-
 
b
 
, IL-1, IL-6, and TNF-
 
a
 
 stimulate osteoclast differ-
entiation and activity via direct or indirect mechanisms,
whereas calcitonin directly inhibits osteoclast activity (6–10).
The fate of osteoclasts after bone resorption is largely un-
known. Certain factors, such as calcitonin, inactivate osteo-
clasts without induction of cell death, whereas other fac-
tors, such as bisphosphonates and vitamin K
 
2
 
, are suggested
to induce apoptosis of osteoclasts (11–13). Apoptosis, or
programmed cell death, is characterized by nucleosomal
DNA fragmentation and grossly changed morphology of
the nuclei without a change in the morphology of the in-
tracellular organelles (14, 15).
Estrogen effects on osteoclasts are thought to be medi-
ated indirectly through nonosteoclastic cells. For instance,
loss of estrogen at menopause or by ovariectomy is associ-
ated with increased secretion of IL-1, IL-6, and TNF-
 
a
 
from the peripheral blood monocytes, bone marrow stro-
mal cells, or osteoblasts, and decreased expression of TGF-
 
b
 
 in
bone (16–19). Elevated levels of these factors result in in-
creased osteoclastogenesis (20). Moreover, Hughes et al.
(21) recently reported that estrogen promoted apoptosis of
murine osteoclast–like cells mediated by TGF-
 
b
 
 in a mixed
cell population in culture. Using a recently developed
technique for isolation of highly purified authentic osteo-
clasts, we showed in this study the direct effects of estrogen
on osteoclastic bone-resorbing activity and osteoclast apop-
tosis. These estrogen effects on osteoclasts were blocked
by treatment with antiestrogens. Moreover, Northern blot
analysis demonstrated abundant estrogen receptor 
 
a
 
 (ER
 
a
 
)
 
1
 
mRNA expression in isolated osteoclasts, suggesting that
estrogen may also have a direct impact on osteoclasts (22–
24). The data presented here indicate that estrogen inhibits
osteoclastic bone resorption activity in part by targeting os-
teoclasts directly to undergo apoptosis through ER-medi-
ated mechanisms.
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Abbreviations used in this paper:
 
 CA II, carbonic anhydrase II; Cat K,
cathepsin K; CT, calcitonin; E
 
2
 
, 17
 
b
 
-estradiol; ER, estrogen receptor;
ICI, ICI164,384; TAM, tamoxifen; TRAcP, tartrate-resistant acid phos-
phatase; TUNEL, TdT-mediated dUTP-biotin nick end-labeling.
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Materials and Methods
 
Osteoclast Preparation.
 
Purified rabbit osteoclasts were pre-
pared by the method of Kakudo et al. (25) from unfractionated
bone cells obtained according to the procedure described by Ta-
kada et al. (26). Briefly, cell suspensions obtained from minced
long bones of 10-d-old rabbits (Japan White; Saitama Experimen-
tal Animals Supply Co., Saitama, Japan) were agitated by vortex-
ing and plated in 10-cm tissue culture dishes (Becton Dickinson
Labware, Lincoln Park, NJ) coated with 0.24% collagen gel
(Nitta Gelatin Co., Tokyo, Japan). After a 3-h incubation, adher-
ent nonosteoclast cells were removed from the collagen gel by se-
quential treatment with 0.001% pronase E and 0.01% collagenase
(Wako Pure Chemical Industries, Osaka, Japan). The remaining
osteoclasts were then collected by 0.1% collagenase solution treat-
ment and replated. When these cell suspensions were seeded onto
tissue culture dishes, osteoclasts attached and spread out on the
dishes. By staining these cells for tartrate-resistant acid phos-
phatase (TRAcP, a marker of osteoclasts) activity using a leuko-
cyte acid phosphatase kit (Sigma Chemical Co., St. Louis, MO)
after a 2-h incubation, we estimated that the purity of the
TRAcP-positive multinucleate cells (
 
.
 
3 nuclei) was 
 
.
 
99% (Fig.
1). When the cells harvested from collagen gels were cultured on
dentine slices, they formed resorption pits as judged by scanning
electron microscopic observation (25). We used these pure osteo-
clast cell suspensions for all experiments.
 
Assay for Osteoclastic Bone-resorbing Activity.
 
In an assay to evaluate
osteoclastic bone-resorbing activity, resorption pits formed by os-
teoclasts on dentine slices were measured for area, and their num-
ber was counted. Briefly, purified osteoclasts were replated onto
dentine slices (circular, 6 mm in diameter) in each well of 96-well
plates (Becton Dickinson) at 150 cells/well and cultured for 24 h
in phenol red–free 
 
a
 
-MEM (Life Technologies, Inc., Grand Is-
land, NY) supplemented with 0.1% BSA (Sigma Chemical Co.).
Dentine slices were then brushed with a rubber policeman to re-
move cells after observation under a fluorescence microscope,
and stained with acid hematoxylin (Sigma Chemical Co.) for 5
min. Total number of pits (reflecting active osteoclast number)
was counted under a light microscope, and total area of resorp-
tion pits (reflecting bone-resorbing activity) was quantified by
densitometric analysis of images of the whole area of dentine
slices put into a computer. 17
 
b
 
-Estradiol (E
 
2
 
) and ICI164,384 (ICI)
were provided by Shionogi Pharmaceuticals Inc. (Osaka, Japan)
and Dr. A.E. Wakeling (ZENECA Pharmaceuticals, Cheshire,
UK), respectively. Tamoxifen (TAM) was obtained from Sigma
Chemical Co. At the point of replating, agents were added to the
cultures at the desired concentrations. At the end of the culture
period, osteoclasts were fixed with formalin–acetone solution
(37% formalin: acetone: 18 mM citric acid/19 mM Na Citrate/
12 mM NaCl; 7:65:25) and stained for TRAcP activity to deter-
mine the osteoclast number on the dentine slices.
 
Osteoclast Apoptosis.
 
The method used to detect osteoclast
apoptosis by fluorescence microscopy was described previously
(27). After treatment with E
 
2
 
, recombinant human TGF-
 
b
 
1
 
(R&D Systems, Minneapolis, MN) or salmon calcitonin (CT;
28), cells were fixed with 2% glutaraldehyde solution (Wako Pure
Chemical Co.) for 10 min, and stained with 0.2 mM Hoechst
33258 for visualization of chromatin condensation under a fluo-
rescence microscope (VANOX AHB-LB, Olympus Co., Tokyo,
Japan). Transmission electron microscopy was performed as fol-
lows. After fixation of osteoclasts on dentine slices with 2%
glutaraldehyde solution for 1 h, the cells were immersed in 0.16 M
EDTA (pH 7.2) and 0.2 M sucrose at 4
 
8
 
C for 2 wk to decalcify
the dentine slices (29), and postfixed in 1% osmium tetraoxide so-
lution (Electron Microscopy Science, Fort Washington, PA) for
1 h. After dehydration in graded ethanol solutions, the cells were
embedded in epoxy resin. Sections were cut, stained with 4%
uranyl acetate, and examined under a transmission electron mi-
croscope (JEM-100CX, JEOL).
 
Northern Blot Analysis.
 
For assessment of the mRNA expres-
sion of osteoclast-specific genes (cathepsin K [Cat K] and car-
bonic anhydrase II [ECA II]), total RNA was extracted by the
AGPC method (30) from osteoclasts cultured on dentine slices in
phenol red–free 
 
a
 
-MEM supplemented with 0.1% BSA with or
without 0.1 nM E
 
2
 
 for 6 or 24 h, and for examination of the
mRNA expression of ERs, osteoclasts isolated by the treatment
with 0.001% pronase E solution (31) were cultured on tissue cul-
ture dishes for 3 h in phenol red–free 
 
a
 
-MEM supplemented
Figure 1. Purified osteoclasts harvested
from collagen gels. 2,000 osteoclasts were
plated on a dentine slice and stained for
TRAcP activity after a 2-h incubation.
(3100). 
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with 0.1% BSA, and then total RNA was extracted by the same
method. The RNA was blotted onto a nitrocellulose membrane
after formaldehyde agarose gel electrophoresis, and Northern blot-
ting was carried out. 
 
32
 
P-labeled radioactive probes were prepared
by the random primer labeling procedure, and the blot was hy-
bridized in 50% formamide/5
 
3
 
 SSPE/5
 
3
 
 Denhart’s reagent/0.2
mg/ml salmon sperm DNA/labeled probe. After hybridization,
the membrane was washed under stringent washing conditions
(0.1
 
3
 
 SSPE/0.1% NaPPi/1% SDS) at 65
 
8
 
C before autoradiogra-
phy. The hybridization probes were rabbit Cat K cDNA (30),
rabbit CA II cDNA, and human ER
 
a
 
 cDNA, all of which were
obtained from American Type Culture Collection (Rockville,
MD). A rat ER
 
b
 
 cDNA was cloned by RT-PCR method from
rat testes. A human 
 
b
 
-actin cDNA probe was used as a reference.
 
TUNEL Assay.
 
To detect in situ DNA fragmentation of
apoptotic osteoclasts, we employed the TUNEL (TdT-mediated
dUTP-biotin nick end-labeling) assay by using a TACS Blue La-
bel
 
Ô
 
 kit (Trevigen, Inc., Gaithersburg, MD) according to the
procedure recommended by the manufacturer.
 
Results and Discussion
 
Estrogen Directly Impacts Osteoclast Function.
 
Direct reduc-
tion of osteoclastic bone resorption by E
 
2
 
 started within 6 h
of treatment (data not shown), and great reduction was ob-
served by 24 h (Fig. 2, 
 
A–C
 
). The ratio of pit area per pit
number was reduced by the treatment with E
 
2
 
, indicating
that E
 
2
 
 inhibition of bone resorption occurred at the level
of individual osteoclast activity (Fig. 2 
 
C
 
, 
 
inset
 
). The level of
inhibition of osteoclastic bone resorption by E
 
2
 
 was compa-
rable to that obtained for calcitonin (Fig. 2 
 
C
 
).
To verify the molecular mechanisms of estrogen-inhib-
ited osteoclastic bone-resorbing activity, we examined
whether E
 
2
 
 would affect the mRNA of Cat K and CA II,
enzymes involved in the bone-resorbing activity of osteo-
clasts. E
 
2
 
 reduced mRNA levels of both Cat K and CA II
in a time-dependent manner (Fig. 3, 
 
A
 
 and 
 
B
 
). Such reduc-
tion was correlated with E
 
2
 
 inhibition of formation of re-
sorption pits by the osteoclasts (data not shown). These
data corresponded to the results that E
 
2
 
 inhibition of bone
resorption occurred at the level of individual osteoclast ac-
tivity (Fig. 2 
 
C
 
, 
 
inset
 
).
Figure 2. Estrogen inhibition of bone resorption by purified rabbit osteoclasts. Purified osteoclasts were incubated with medium (A) lacking or (B)
containing 0.1 nM E2 for 24 h on dentine slices (340). After removal of osteoclasts, resorption pits formed by osteoclasts were stained with acid hema-
toxylin and observed under a light microscope. (C) Inhibitory effects of E2 on osteoclast-mediated bone resorption. Purified osteoclasts were cultured on
dentine slices (150 cells/slice) in medium (Con) or in medium containing 0.001–1 nM E2 (E2) or 1 nM salmon calcitonin (CT). Osteoclastic bone resorp-
tion activity was measured in terms of pit area formed by purified osteoclasts after 24 h of incubation. Pit area per pit number is also indicated (inset). Val-
ues are means 6 SD, n 5 4. *P ,0.05, **P ,0.01, ***P ,0.005 compared with control groups. Data are representatives of those obtained in three addi-
tional independent experiments.
Figure 3. Negative regulation of mRNA levels for Cat K and CA II by
estrogen. (A) Northern blot analysis. Total RNAs (3 mg) from z25,000
purified osteoclasts cultured on dentine slices (150 cells/dentine slices)
with (E2) or without 0.1 nM E2 (Con) for 6 or 24 h were used as samples.
(B) Relative abundance of Cat K and CA II mRNAs. The relative abun-
dance of Cat K and CA II mRNAs on Northern blotting was evaluated
from the values of densitometric scanning. The values shown were nor-
malized with respect to the abundance of b-actin (ACT), and expressed as
means 6 SD of samples from three other independent experiments. 
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Estrogen Directly Promotes Osteoclast Apoptosis. To un-
derstand the mechanism of estrogen-induced osteoclast in-
activation, we evaluated the morphological changes in osteo-
clasts  upon estrogen treatment at the subcellular level.
Apoptosis is quite different from necrosis, which is accom-
panied by cell disintegration, and provides an organized
means of cell death to minimize damage to the surrounding
cells (32). To examine direct effects of estrogen on osteo-
clast apoptosis, we observed pure authentic osteoclasts at-
tached to dentine slices in this study, as .90% of the osteo-
clasts plated remained attached to the dentine slices after 24 h
of cultures. Moreover, we confirmed by video monitoring
that osteoclasts did not detach easily even during the mor-
phological change to the apoptotic appearance, especially
up to 24 h (data not shown). After 24 h of E2 treatment,
osteoclasts displayed characteristics of apoptosis, including
chromatin condensation and grossly changed cellular and
nuclear morphology as detected by fluorescence micros-
copy (Fig. 4 A). These observations were further confirmed
by transmission electron microscopy (Fig. 4 C). E2 treat-
ment did not change the morphology of intracellular or-
ganelles of osteoclasts, and cell membranes remained intact
(Fig. 4 C). Such features are characteristic of apoptosis, and
clearly indicated that the cause of cell death was not necro-
sis, which is accompanied by cellular disintegration (14,
15). Furthermore, in situ DNA fragmentation in these cells
was detected by the TUNEL method (Fig. 4 B). The num-
ber of DNA fragment–bearing osteoclasts (TUNEL-posi-
Figure 4. Estrogen-induced osteoclast apoptosis. Osteoclasts were cultured on dentine slices with 0.1 nM E2 for 24 h. (A) A fluorescence micrograph
shows normal and apoptotic osteoclasts (arrowhead) attached to a dentine slice in a 24-h culture. 3250. (B) The TUNEL assay indicates DNA fragmenta-
tion in an apoptotic osteoclast. 3250. (C) This micrograph, obtained by electron transmission microscopy, demonstrates the gross morphological changes
in an apoptotic osteoclast. Nuclear fragments are indicated by the arrowheads. 32,000.
Figure 5. Dose- and time-dependent manner of estrogen-induced os-
teoclast apoptosis. (A) Purified osteoclasts were cultured on dentine slices
(150 cells/slice) for 24 h in medium (Con) or in medium containing
0.001–1 nM E2, 1–20 ng/ml TGF-b1, or 1 nM CT. Apoptotic osteoclasts
were quantified under a fluorescence microscope. (B) Time-dependent
effects of E2 on osteoclast apoptosis and osteoclast number. Under the
same culture conditions, purified osteoclasts were incubated in medium
without 0.1 nM E2 (apoptosis: s; cell number: u) or with 0.1 nM E2
(apoptosis: d, cell number: j) for 6, 12, or 24 h. Apoptotic osteoclasts
are expressed as a percentage of total number of adherent osteoclasts. Val-
ues are means 6 SD, n 5 4. *P ,0.05, **P ,0.005 compared with time 5 0
groups. Data are representative of those of three additional independent
experiments.493 Kameda et al.
tive cells) was correlated with the number of morphological
apoptotic osteoclasts detected by Hoechst 33258 staining. In
unfractionated bone cells, E2 also induced osteoclast apop-
tosis without causing changes in nonosteoclastic cells (data
not shown).
Quantification of E2-induced osteoclast apoptosis showed
a dose-dependent increase (Fig. 5 A), which correlated
with the dose range of E2 for inhibition of bone resorption
(Fig. 2 B). In contrast to estrogen, calcitonin, which inhib-
its osteoclast activity directly through its receptors on os-
teoclasts, did not cause osteoclasts to undergo apoptosis,
suggesting that inhibition of osteoclastic bone resorption by
E2 is mediated by a distinctively different mechanism than
that used by calcitonin. As for detached cells, significant
cellular disintegration prevented us from detecting osteo-
clast apoptosis in them in 24-h and older cultures. E2-induced
osteoclast apoptosis was also time dependent (Fig. 5 B). E2
(0.1 nM) inhibition of formation of resorption pits by os-
teoclasts was correlated with a reduction in the expression
of mRNAs for Ca K and CA II and with an increased in-
duction of osteoclast apoptosis in a time course study.
These findings suggest that E2 directly acts on osteoclasts
and inhibits osteoclastic bone resorption by causing osteo-
clast inactivation partially due to apoptosis. A recent report
indicated that estrogen promoted TGF-b–mediated apop-
tosis of in vitro–developed murine osteoclast-like cells in
mixed cell cultures (21). TGF-b1 (10 ng/ml) induces apop-
tosis of our pure authentic osteoclasts. However, the inci-
dence was lower than that by E2 treatment in our mature
cells or that of TGF-b–induced apoptosis in murine mixed
cell cultures (Fig. 5 A, reference 21). The causes of this dis-
crepancy might be partially due to their different species;
however, these results suggest that estrogen-enhanced os-
teoclast apoptosis mediated by TGF-b might occur in an
indirect manner. The direct induction of osteoclast apop-
tosis by estrogen besides indirect induction might exist.
Figure 6. Estrogen affects osteoclasts through ER-mediated mechanisms. (A) Antiestrogens recovered E2-inhibited osteoclastic bone resorption. ICI at
1 nM or 1 nM TAM was added to osteoclast cultures in the presence or absence of 0.1 nM E2 or 1 nM salmon CT. 24 h later, osteoclastic bone resorp-
tion activity was measured in terms of pit area. (B) Antiestrogens blocked E2-induced osteoclast apoptosis. Under the same culture conditions, purified os-
teoclasts were incubated in medium with or without 1 nM ICI or 1 nM TAM in the presence or absence of 0.1 nM E2, and osteoclast apoptosis was mea-
sured after a 24-h treatment. Apoptotic osteoclasts are expressed as a percentage of total number of adherent osteoclasts. (C) Northern blot analysis of
ERa and ERb mRNA expression in osteoclasts. Total RNA (50 mg) from z5 3 105 purified osteoclasts cultured on tissue culture dishes with 0.1 nM
E2 for 6 h were used as samples. Values are means 6 SD, n 5 4. *P ,0.05, **P ,0.01, ***P ,0.005 compared with control or estrogen-treated groups
for A and B. Data are representative of those of three additional independent experiments.494 Direct Induction of Osteoclast Apoptosis by Estrogen
Estrogen Inhibits Osteoclastic Bone-resorbing Activity and Pro-
motes Osteoclast Apoptosis Through ER-mediated Mechanisms.
Using a pure or a partial antagonist which can block estro-
gen effects by binding to the ER, we examined whether
these estrogen effects on osteoclasts were ER mediated or
not. ICI, a pure antiestrogen, had no effect on pit forma-
tion when expressed in terms of pit area, whereas TAM, a
partial estrogen antagonist, partially inhibited the resorption
activity of purified osteoclasts (Fig. 6 A). When combined
with E2, both ICI and TAM reversed the inhibitory effect
of E2, indicating that E2 inhibited osteoclastic bone-resorb-
ing activity through ER. In contrast, the inhibitory effect
of calcitonin was not affected by either ICI or TAM (Fig. 6
A). Consistent with their lack of, or partial, ability to in-
hibit pit formation, ICI (0.001–100 nM) did not induce
apoptosis of osteoclasts, whereas TAM induced osteoclast
apoptosis partially at 1 nM , but not in a statistically signifi-
cant manner, at 0.001–0.1 nM or at 10–100 nM (Fig. 6 B,
data not shown). These contradictory effects of antiestro-
gens might be due to variety of ERs and coregulators (33,
34). When combined with E2, ICI and TAM blocked E2-
induced osteoclast apoptosis as a pure or partial antagonist,
respectively (Fig. 6 B, actual number of attached osteo-
clasts, plated at 150 cells, onto dentine slice after 24 h of
culture: control, 143.5 6 5.2; 1 nM ICI, 139.5 6 7.3; 1
nM TAM, 141.0 6 7.8; 0.1 nM E2, 137.0 6 10.9; 0.1 nM
E2 1 1 nM ICI, 141.0 6 7.2; 0.1 nM E2 1 1 nM TAM,
136.9 6 7.8). These results suggest that estrogen effects on
osteoclasts might be mediated by the ER and not be a con-
sequence of toxicity. Only a high dose of TAM was re-
ported to be able to induce osteoclast apoptosis in rat os-
teoclasts as well as E2 treatment (35). In this culture system,
however, the optimal concentration of TAM for both in-
ducing osteoclast apoptosis and rescuing osteoclasts from
undergoing apoptosis by the treatment with E2 was 1 nM,
which might be due to partial mimicking of estrogen ef-
fects. TAM may act on osteoclasts as a partial agonist rather
than as a partial antagonist.
Several isoforms of ERa and one subtype of ER, called
ERb, have been reported (36–38). In rabbit osteoclasts, we
previously demonstrated the expression of mRNAs (z1.5,
2, and 6 kb with the 6-kb mRNA considered to be puta-
tive ERa mRNA) which hybridized with ERa cDNA in
Northern blots (22). In this study, Northern blot analysis
revealed that osteoclasts expressed ERa mRNA, but ERb
mRNA was undetectable (Fig. 6 C). ER cDNA-hybridiz-
ing mRNAs besides putative ERa in pure osteoclasts might
be isoforms of ERa mRNA or some other mRNA but not
ERb mRNA. These data suggest that rabbit osteoclasts
might be controlled by estrogen through ERas.
In conclusion, the data presented in this study demon-
strate that in addition to the indirect effects of estrogen on
bone resorption mediated by soluble factors secreted from
nonosteoclastic cells and cell-to-cell contact with nonosteo-
clastic cells, estrogen can function directly on osteoclasts to
inhibit their bone-resorbing activity. The ability of estro-
gen to induce apoptosis of osteoclasts at correlative concen-
trations effective for inhibition of bone resorption may be
the mechanism underlying such effects. The effects of the
antiestrogens also suggest that osteoclast apoptosis induced
by estrogen is mediated by the ER. These findings, there-
fore, may shed new light on our understanding of the cel-
lular mechanism by which estrogen provides protective ef-
fects on the skeleton, and support the validity of using
estrogen replacement therapy for treating postmenopausal
osteoporosis.
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